Pharmaceutical News

RSS

African sleeping sickness parasite has defence mechanism against potential pharmaceuticals

Researchers from Umea University in Sweden have discovered that the single-celled parasite causing African sleeping sickness has a defence mechanism against potential pharmaceuticals under development against the disease. The deadly parasite has an enzyme that can cleave and hence disarm adenosine analogue pharmaceuticals. This according to a study recently published in the Journal of Biological Chemistry.

18 Apr 2016

MGH-led study confirms safety of allergy immunotherapy

A team of Massachusetts General Hospital investigators has found no evidence of infections related to administration of allergy immunotherapy, the common practice of injecting minimal quantities of allergens beneath the skin to reduce the allergic response.

18 Apr 2016

Study supports screening for HLA-B*5801 gene variant in Asian, black patients with gout

A multi-institutional study led by a Massachusetts General Hospital investigator finds significant racial disparities in the risk that patients being treated for gout will develop a serious, sometimes life-threatening adverse reaction to the most commonly prescribed medication. The increased risk closely correlates with the frequency of a gene variant previously associated with that adverse reaction, supporting recommendations to screen for that variant in patients from those populations.

16 Apr 2016

New oral blood thinners can decrease stroke risk in atrial fibrillation patients without frequent monitoring

A new generation of blood thinners can reduce the risk of stroke in patients with atrial fibrillation, without requiring frequent monitoring and dietary restrictions.

16 Apr 2016

Palovarotene drug may prevent multiple musculoskeletal problems linked with FOP

New research in laboratory animals suggests that the drug palovarotene may prevent multiple skeletal problems caused by a rare but extremely disabling genetic bone disease, and may even be a candidate for use in newborn babies with the condition.

15 Apr 2016

Scientists find new way to defend against deadly malarial parasite

The most dangerous malaria parasite, Plasmodium falciparum, is responsible for nearly half a million deaths annually across Africa and Southeast Asia. Of increasing concern, this parasite is now developing resistance to common antimalarial drugs.

15 Apr 2016

High dosages of antihistamines have dulling effect on genes associated with post-exercise recovery

After vigorous exercise, some 3,000 genes go to work to aid recovery by boosting muscles and blood vessels, but in the presence of high doses of antihistamines almost 27 percent of the gene response is blunted, according to University of Oregon researchers.

15 Apr 2016

Taking antibiotics in early childhood can disrupt immune system function lifelong

Scientists want to know whether taking antibiotics early in life can disrupt your immune system function lifelong.

15 Apr 2016

Proliposomal ropivacaine may offer valuable new option for pain relief

A new "proliposomal" preparation of the local anesthetic drug ropivacaine may provide a valuable new option for pain relief in some clinical situations, with key advantages over other types of slow-release local anesthetics, suggest a pair of reports in Anesthesia & Analgesia.

15 Apr 2016

Pluristem granted two key cell therapy patents in Japan

Pluristem Therapeutics Inc. (PSTI), a leading developer of placenta-based cell therapy products, has announced that the Japan Patent Office has granted the Company two key patents addressing...

14 Apr 2016

Innate Immunotherapeutics announces clinical trial fully enrolled and receives strong interest from potential Pharma partners

Innate Immunotherapeutics Limited has closed enrolment into the Company's Phase 2B placebo controlled efficacy trial of MIS416 in patients with secondary progressive multiple sclerosis (SPMS). The study has exceeded the original recruitment target of 90 subjects with the successful enrolment this week of the 93rd patient.

14 Apr 2016

HCV patients with hepatocellular carcinoma history could re-develop illness during or after taking DAAs

Data from a new study show that patients with Hepatitis C virus (HCV) taking direct-acting antiviral treatments (DAAs), who have previously fought off hepatocellular carcinoma (HCC), the most common form of liver cancer,1 had a 'high rate' of re-developing their illness.

13 Apr 2016

Studies offer alternative conclusions on efficacy of DAAs for HIV and HCV co-infected patients

Two separate studies presented today at The International Liver Congress 2016 in Barcelona, Spain have offered alternative conclusions regarding the efficacy of direct-acting antivirals (DAAs) among patients co-infected with HIV and Hepatitis C virus (HCV).

13 Apr 2016

Prime boost approach can increase possibility of combined HCV and HIV vaccination

A combined vaccination against Hepatitis C virus (HCV) and HIV moved a step closer, with the results of a study presented at The International Liver Congress 2016 in Barcelona, Spain today.

13 Apr 2016

Study reveals low rates of targeted drug use among older black women with early-stage breast cancer

The advent of targeted drugs for a specific type of breast cancer - HER2 positive - has dramatically improved survival rates for women with the disease. But a study led by researchers at the University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center reveals low rates of use of a targeted drug among older women with early-stage breast cancer of this type, and even lower rates for older black women.

13 Apr 2016

Common antihistamine may partially reverse damage to visual system in multiple sclerosis patients

A common antihistamine used to treat symptoms of allergies and the common cold, called clemastine fumarate, partially reversed damage to the visual system in people with multiple sclerosis (MS) in a preliminary study released today that will be presented at the American Academy of Neurology's 68th Annual Meeting in Vancouver, Canada, April 15 to 21, 2016.

13 Apr 2016

Researchers reach milestone in developing non-hormonal approach to male contraception

Researchers studying strategies to develop a non-hormonal approach to male contraception have reached an important milestone in their work, discovering a way to produce a key enzyme found only in sperm in sufficient quantities that they can begin designing drugs to stop the sperm from swimming to the egg.

13 Apr 2016

Researchers aim to design stable micro-bubbles containing chemotherapeutic drugs

Researchers are now working to design stable micro-bubbles which, combined with ultrasound, can deliver cancer drugs straight to the target tumour.

13 Apr 2016

Novel antibiotics to overcome antibacterial resistance

Small and innovative pharmaceutical companies, with products in early stages of development, presented some of their novel approaches and antimicrobial therapies under development during a dedicated session at the annual congress (ECCMID) of the European Society of Clinical Microbiology and Infectious Diseases(ESCMID) in Amsterdam.

13 Apr 2016

Dual-acting hybrid drug could be a promising new weapon against drug-resistant malaria

A combination of artemisinin and another drug (artemisinin combination therapy, ACT) is currently the best malaria treatment recommended by the World Health Organization.

12 Apr 2016

Pharmaceutical News

African sleeping sickness parasite has defence mechanism against potential pharmaceuticals

MGH-led study confirms safety of allergy immunotherapy

Study supports screening for HLA-B*5801 gene variant in Asian, black patients with gout

New oral blood thinners can decrease stroke risk in atrial fibrillation patients without frequent monitoring

Palovarotene drug may prevent multiple musculoskeletal problems linked with FOP

Scientists find new way to defend against deadly malarial parasite

High dosages of antihistamines have dulling effect on genes associated with post-exercise recovery

Taking antibiotics in early childhood can disrupt immune system function lifelong

Proliposomal ropivacaine may offer valuable new option for pain relief

Pluristem granted two key cell therapy patents in Japan

Innate Immunotherapeutics announces clinical trial fully enrolled and receives strong interest from potential Pharma partners

HCV patients with hepatocellular carcinoma history could re-develop illness during or after taking DAAs

Studies offer alternative conclusions on efficacy of DAAs for HIV and HCV co-infected patients

Prime boost approach can increase possibility of combined HCV and HIV vaccination

Study reveals low rates of targeted drug use among older black women with early-stage breast cancer

Common antihistamine may partially reverse damage to visual system in multiple sclerosis patients

Researchers reach milestone in developing non-hormonal approach to male contraception

Researchers aim to design stable micro-bubbles containing chemotherapeutic drugs

Novel antibiotics to overcome antibacterial resistance

Dual-acting hybrid drug could be a promising new weapon against drug-resistant malaria

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News